Professor Dyfrig Hughes
Athro mewn Ffarmacoeconomeg / Cyfarwyddwr Ymchwil
- Paper › Research › Not peer-reviewed
- Published
Pharmacokinetics, patient compliance and pharmaeconomics
Hughes, D. & Hughes, D. A., 1 Jun 2005.Research output: Contribution to conference › Paper
- Published
Pharmacometric analysis of duration of drug action: implications for improved forgiveness to medication non-compliance
Hughes, D., Hughes, D. A. & Walley, T., 1 Sept 2001.Research output: Contribution to conference › Paper
- Published
Physchiatrist prescribing preferences and attitudes toward promotion
Hughes, D., Menkes, D., Davies, R. & Hughes, D. A., 1 Apr 2006.Research output: Contribution to conference › Paper
- Published
Population pharmacokinetics of warfarin: Intermin analysis of the Liverpool pharmacogenetic prospective cohort study
Hughes, D., Matthews, I., Aarons, L., Al-Zubiedi, S., Hatch, E., Lane, S., Williamson, P., Kamali, F., Hughes, D. A. & Pirmohamed, M., 1 Nov 2007.Research output: Contribution to conference › Paper
- Published
Pragmatic trials - design features and implications for clinical decision making
Hughes, D., Urdahl, H., Hughes, D. A. & Freemantle, N., 1 Aug 2000.Research output: Contribution to conference › Paper
- Published
Prescription fee exemption research study
Hughes, D., Myles, S., Hughes, D. A., Routledge, P. & Wales, D. F., 1 Jun 2006.Research output: Contribution to conference › Paper
- Published
Public funding of drugs for orphan diseases
Hughes, D. & Hughes, D. A., 1 Jul 2005.Research output: Contribution to conference › Paper
- Published
Public funding of drugs for orphan diseases
Hughes, D. & Hughes, D. A., 1 Jan 2006.Research output: Contribution to conference › Paper
- Published
Public funding of drugs for orphan diseases
Hughes, D. & Hughes, D. A., 1 Nov 2005.Research output: Contribution to conference › Paper
- Published
Public funding of drugs for orphan diseases
Hughes, D. & Hughes, D. A., 1 Nov 2005.Research output: Contribution to conference › Paper
- Published
Public meetings of the NICE appraisals committee
Hughes, D. & Hughes, D. A., 1 Dec 2007.Research output: Contribution to conference › Paper
- Published
Quantitative risk-benefit analysis
Hughes, D. & Hughes, D. A., 1 May 2007.Research output: Contribution to conference › Paper
- Published
Rationing of drugs for rare diseases
Hughes, D. & Hughes, D. A., 1 Apr 2006.Research output: Contribution to conference › Paper
- Published
Systematic review of follow-up of cancer in primary care verses secondary care: findings for breast and lung cancer
Hughes, D., Lewis, R., Neal, R. D., France, B., Williams, N. H., Wilkinson, C., Russell, I. T., Russell, D., Hughes, D. A., Stuart, N. S. & Weller, D., 1 Mar 2007.Research output: Contribution to conference › Paper
- Published
The all wales medicines strategy group: assessments and appraisals
Hughes, D. & Hughes, D. A., 1 Nov 2008.Research output: Contribution to conference › Paper
- Published
The assessment, determinants & economics of medication compliance & persistence
Hughes, D., Hughes, D. A., Gwadry Sridhar, F. & Elliott, R., 1 Oct 2007.Research output: Contribution to conference › Paper
- Published
The cost-effectiveness of biological therapies for Crohn's disease: Markov cohort analyses incorporating UK patient-level cost data
Hughes, D., Bodger, K., Kikuchi, T. & Hughes, D. A., 1 Mar 2008.Research output: Contribution to conference › Paper
- Published
The cost-effectiveness of biological therapies for Crohn's disease: markov cohot analyses incorporating UK patient-level cost data
Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 May 2008.Research output: Contribution to conference › Paper
- Published
The economics of evergreening.
Hughes, D. & Hughes, D. A., 1 Jan 2009.Research output: Contribution to conference › Paper
- Published
The effect of compliance upon clinical effectiveness of chlorproguanil-dapsone (CD) and artemether-lumefantrine (AL) when compared to sulfadoxine-pyrimethamine (SP) for the treatment of uncomplicated falcipaum malaria in Malawi - a randomised controlled trial
Hughes, D., Bell, D. J., Wootton, D., Mukaka, M., Montgomery, J., Kayange, N., Chimpeni, P., Zijlstra, E., Hughes D.A., [. V., Molyneux M.E.*, [. V., Ward, S. A., Winstanley, P. A. & Lalloo, D. G., 1 Nov 2007.Research output: Contribution to conference › Paper
- Published
The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies
Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Nov 2000.Research output: Contribution to conference › Paper
- Published
The pharmacokinetic profile of Warfarn: a systematic review
Hughes, D., Al-Zubiedi S.*, [. V., Hughes D.A., [. V. & Pirmohamed, M., 1 Dec 2007.Research output: Contribution to conference › Paper
- Published
The population pharmacokinetics of lapdap
Hughes, D., Ward, S., Simpson, J., Aarons, L., Szwandt, S. & Hughes, D. A., 1 Nov 2002.Research output: Contribution to conference › Paper
- Published
Ultra-long acting pharmaceuticals: Do they result in better outcomes, and at an acceptable cost?
Hughes, D. & Hughes, D. A., 1 Nov 2006.Research output: Contribution to conference › Paper
- Published
Use of PK-PD modelling to predict the impact of non-compliance
Hughes, D. & Hughes, D. A., 1 Nov 2003.Research output: Contribution to conference › Paper
- Published
What determines which interventions improve compliance, and do they improve health outcomes in a cost-effective manner?
Hughes, D., Hughes, D. A., LaFleur.*, [. V., Salas, M. & Shinogle, J., 1 May 2007.Research output: Contribution to conference › Paper
- Paper › Research › Peer-reviewed
- Published
A Systematic Review of Patient Preferences for Subcutaneous Medications
Ridyard, C., Dawoud, D. & Hughes, D., Nov 2013.Research output: Contribution to conference › Paper › peer-review
- Published
Identification Of Items For A Standardised Resource-Use Measure: Review Of Current Instruments
Thorn, J. C., Ridyard, C., Riley, R., Brookes, S., Hughes, D., Wordsworth, S., Noble, S. & Hollingworth, W., Nov 2015.Research output: Contribution to conference › Paper › peer-review
- Published
Review of the Use of Resource Use Instruments Based on Patient Recall in Relation to Other Methods of Cost Estimation
Ridyard, C. & Hughes, D., Nov 2013.Research output: Contribution to conference › Paper › peer-review
- Published
Review of the use of resource use instruments based on patient recall in relation to other methods of resource use estimation
Ridyard, C. & Hughes, D., Nov 2013.Research output: Contribution to conference › Paper › peer-review
- Published
Screening log data can be used to inform protocol modifications, increasing patient recrutiment to a challanging clinical trial
Blair, J., Awoyale, L., Thornborough, K., Peak, M., Didi, M., Bedson, E., Hughes, D., Ridyard, C., Tat, T. & Gregory, J., Nov 2013.Research output: Contribution to conference › Paper › peer-review
- Poster › Research › Peer-reviewed
- Published
Carer-administration of as-needed sub-cutaneous medication for breakthrough symptoms in homebased dying patients: a UK study (CARIAD)
Wilkinson, C., Poolman, M., Roberts, J., Wee, B., Hiscock, J., Hughes, D., Nelson, A., Perkins, P., Johnstone, R. P., Reymond, E., Foster, B., O'Connor, J., Jones, S., Hoare, Z., Roberts, R., Byrne, A., Healy, S. & Lewis, P., 1 Sept 2017.Research output: Contribution to conference › Poster › peer-review
- Published
Comparison of regression methods for the cost effectiveness analysis of clinical trials with a small population size: the sycamore and folated trials
Culeddu, G., Hughes, D. & Welton, N., 10 Jul 2017.Research output: Contribution to conference › Poster › peer-review
- Published
Core items for a standardised resource-use measure (ISRUM):expert Delphi consensus survey
Thorn, J., Ridyard, C., Riley, R., Brookes, S., Hughes, D., Wordsworth, S., Noble, S., Thornton, G. & Hollingworth, W., 7 May 2017, p. P265. 1 p.Research output: Contribution to conference › Poster › peer-review
- Published
Health Economics Analysis Plans: Where Are We Now?
Thorn, J., Ridyard, C., Hughes, D., Wordsworth, S., Mihaylova, B., Noble, S. & Hollingworth, W., 3 Nov 2016, p. A397. 1 p.Research output: Contribution to conference › Poster › peer-review
- Published
Health economics analysis plans: the current state of play
Thorn, J., Ridyard, C., Hughes, D., Wordsworth, S., Mihaylova, B., Noble, S. & Hollingworth, W., 7 May 2017, p. P144. 1 p.Research output: Contribution to conference › Poster › peer-review
- Published
Patient-level information and costing systems (PLICS) as a source of routinely collected cost data for trial-based economic evaluations
Ridyard, C. & Hughes, D., 7 May 2017, p. P141. 1 p.Research output: Contribution to conference › Poster › peer-review
- Abstract › Research › Peer-reviewed
- Published
Continuous subcutaneous insulin infusion compated to multiple daily injection regimens in children and yung people at diagnosis of type 1 diabetes: A pragmatic randomised controlled trial and economic evaluation (scipi trial)
Blair, J., Mckay, A., Ridyard, C., Thornborough, K., Bedson, E., Peak, M., Didi, M., Annan, F., John, G., Hughes, D. & Gamble, C., Sept 2017, p. 22-23.Research output: Contribution to conference › Abstract › peer-review
- Other › Research › Peer-reviewed
- Published
Cost-Effectiveness Analysis of Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa
Culeddu, G., Brogan, P. A. & Hughes, D., 2021.Research output: Contribution to conference › Other › peer-review
- Commissioned report › Research › Not peer-reviewed
- Published
A review of economic models for second-line chemotherapy in the management of advanced, metastatic breast cancer.
Hughes, D. & Hughes, D. A., 1 Jan 2001, 2001 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
AWMSG criteria for appraising new medicines.
Hughes, D. & Hughes, D. A., 1 Jan 2007, 2007 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Ambrisentan (Volibris) for pulmonary arterial hypertension.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2009, 2009 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Anidulafungin (Ecalta) for the treatment of invasive candidiasis in adult non-neutropenic patients.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2009, 2009 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Buprenorphine/naloxone (Suboxone) as substitution treatment for opioid dependence.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Deferasirox (Exjade) for the treatment of chronic iron overload due to blood transfusions.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Docetaxel (Taxotere) for locally advanced squamous cell carcinoma of the head and neck.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report